Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 1/2024

01.01.2025 | Research

Omission of axillary lymph node dissection in breast cancer patients with micrometastasis or isolated tumor cells in sentinel lymph nodes: a 12-year experience in a tertiary breast unit

verfasst von: Nuno Sousa, Bárbara Peleteiro, José Luis Fougo

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Introduction

After the IBCSG 23–01 trial, our breast center no longer performed axillary lymph node dissection (ALND) after detection of isolated tumor cells (ITC) or micrometastasis in the sentinel lymph nodes (SLN). A recent study suggested that up to half of the patients with micrometastasis in the SLN could benefit from ALND in terms of disease-free survival (DFS) and overall survival (OS).

Methods

This retrospective, unicentric, study analyzed 261 consecutive cT1-3 cN0 breast cancer patients with ITC or micrometastasis in their SLN. Primary objective was comparison of ALND vs. SLN biopsy (SLNB) with regard to DFS and OS. Secondary objectives included analysis of factors associated with an increased rate of locoregional recurrence (LRR), distant metastasis (DM) and metachronous contralateral breast cancer (MCBC).

Results

DFS events occurred in 19 patients (7.3%) and 14 patients died (5.4%). Median follow-up time was 78 months. 251 patients (96.2%) had micrometastasis in their SLN. There was no difference in the OS or DFS of ALND vs. SLNB patients. History of previous contralateral breast cancer and WBI were associated with an increased and decreased rate of LRR, respectively. Larger tumor size was associated with an increased rate of DM. Non-ductal histological types were associated with an increased rate of MCBC.

Discussion

Avoiding ALND may be safe in pN1mi/pN0(i+) patients. Besides, we strongly encourage clinicians to develop their own follow-up protocols based on the best available evidence, to rapidly identify and treat breast cancer recurrence.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
Zurück zum Zitat Begg CB, Ostrovnaya I, Geyer FC, Papanastasiou AD, Ng CKY, Sakr RA, Bernstein JL, Burke KA, King TA, Piscuoglio S, Mauguen A, Orlow I, Weigelt B, Seshan VE, Morrow M, Reis-Filho JS (2018) Contralateral breast cancers: independent cancers or metastases? Int J Cancer 142:347–356. https://doi.org/10.1002/ijc.31051CrossRefPubMed Begg CB, Ostrovnaya I, Geyer FC, Papanastasiou AD, Ng CKY, Sakr RA, Bernstein JL, Burke KA, King TA, Piscuoglio S, Mauguen A, Orlow I, Weigelt B, Seshan VE, Morrow M, Reis-Filho JS (2018) Contralateral breast cancers: independent cancers or metastases? Int J Cancer 142:347–356. https://​doi.​org/​10.​1002/​ijc.​31051CrossRefPubMed
Zurück zum Zitat Espinosa-Bravo M, Ramos T, Aizpurua GM, Sao AA, Peg CV, Sancho M, Gónzalez-Orus JM, Xercavins MJ, Ramos M, Rubio IT (2011) P3-07-11: multicenter comparative study between One-Step Nucleic Acid Amplification (OSNA) whole node assay and standard frozen section histology: intraoperative molecular assay for sentinel lymph node metastases in early breast cancer can avoid a second surgery. Cancer Res 71:P3-07-11-P3-07–11. https://doi.org/10.1158/0008-5472.SABCS11-P3-07-11CrossRef Espinosa-Bravo M, Ramos T, Aizpurua GM, Sao AA, Peg CV, Sancho M, Gónzalez-Orus JM, Xercavins MJ, Ramos M, Rubio IT (2011) P3-07-11: multicenter comparative study between One-Step Nucleic Acid Amplification (OSNA) whole node assay and standard frozen section histology: intraoperative molecular assay for sentinel lymph node metastases in early breast cancer can avoid a second surgery. Cancer Res 71:P3-07-11-P3-07–11. https://​doi.​org/​10.​1158/​0008-5472.​SABCS11-P3-07-11CrossRef
Zurück zum Zitat Fougo JL, Amendoeira I, Brito MJ, Correia AP, Gonçalves A, Honavar M, Machado A, Magalhães A, Marta S, Nogueira M, Peleteiro B, Pontes P (2020) Sentinel node total tumour load as a predictive factor for non-sentinel node status in early breast cancer patients—the porttle study. In: Surg Oncol, Elsevier Ltd, pp 108–114. https://doi.org/10.1016/j.suronc.2019.11.008 Fougo JL, Amendoeira I, Brito MJ, Correia AP, Gonçalves A, Honavar M, Machado A, Magalhães A, Marta S, Nogueira M, Peleteiro B, Pontes P (2020) Sentinel node total tumour load as a predictive factor for non-sentinel node status in early breast cancer patients—the porttle study. In: Surg Oncol, Elsevier Ltd, pp 108–114. https://​doi.​org/​10.​1016/​j.​suronc.​2019.​11.​008
Zurück zum Zitat Galimberti V, Botteri E, Chifu C, Gentilini O, Luini A, Intra M, Baratella P, Sargenti M, Zurrida S, Veronesi P, Rotmensz N, Viale G, Sonzogni A, Colleoni M, Veronesi U (2012) Can we avoid axillary dissection in the micrometastatic sentinel node in breast cancer? Breast Cancer Res Treat 131:819–825. https://doi.org/10.1007/s10549-011-1486-2CrossRefPubMed Galimberti V, Botteri E, Chifu C, Gentilini O, Luini A, Intra M, Baratella P, Sargenti M, Zurrida S, Veronesi P, Rotmensz N, Viale G, Sonzogni A, Colleoni M, Veronesi U (2012) Can we avoid axillary dissection in the micrometastatic sentinel node in breast cancer? Breast Cancer Res Treat 131:819–825. https://​doi.​org/​10.​1007/​s10549-011-1486-2CrossRefPubMed
Zurück zum Zitat Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P, Baratella P, Chifu C, Sargenti M, Intra M, Gentilini O, Mastropasqua MG, Mazzarol G, Massarut S, Garbay JR, Zgajnar J, Galatius H, Recalcati A, Littlejohn D, Bamert M, Colleoni M, Price KN, Regan MM, Goldhirsch A, Coates AS, Gelber RD, Veronesi U (2013) Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial. Lancet Oncol 14:297–305. https://doi.org/10.1016/S1470-2045(13)70035-4CrossRefPubMedPubMedCentral Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P, Baratella P, Chifu C, Sargenti M, Intra M, Gentilini O, Mastropasqua MG, Mazzarol G, Massarut S, Garbay JR, Zgajnar J, Galatius H, Recalcati A, Littlejohn D, Bamert M, Colleoni M, Price KN, Regan MM, Goldhirsch A, Coates AS, Gelber RD, Veronesi U (2013) Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial. Lancet Oncol 14:297–305. https://​doi.​org/​10.​1016/​S1470-2045(13)70035-4CrossRefPubMedPubMedCentral
Zurück zum Zitat Galimberti V, Cole BF, Viale G, Veronesi P, Vicini E, Intra M, Mazzarol G, Massarut S, Zgajnar J, Taffurelli M, Littlejohn D, Knauer M, Tondini C, Di Leo A, Colleoni M, Regan MM, Coates AS, Gelber RD, Goldhirsch A, Boyle F, Jerusalem G, Stahel R, Aebi S, Green M, Karlsson P, Kössler I, Láng I, Hiltbrunner A, Bernhard J, Fournarakou S, Kammler R, Maibach R, Rabaglio M, Ribi K, Roschitzki H, Roux S, Ruepp B, Mahoney C, Price K, Blacher L, Scolese T, Scott K, Lippert S, Zielinski T, Mastropasqua M, Andrighetto S, Dell’Orto P, Renne G, Pruneri G, Dellapasqua S, Iorfida M, Cancello G, Montagna E, Cardillo A, Peruzzotti G, Ghisini R, Luini A, Veronesi U, Intra M, Gentilini O, Zurrida S, Curigliano G, Nole F, Orecchia R, Leonardi MC, Baratella P, Chifu C, Sargenti M, Crivellari D, Morassut S, Mileto M, Piccoli E, Veronesi A, Magri MD, Buonadonna A, Candiani E, Carbone A, Perin T, Volpe R, Roncadin M, Arcicasa M, Coran F, Lagrassa M, Recalcati A, Limonta ME, Tricomi P, Fenaroli P, Candiago E, Cattaneo L, Gianatti A, Santini D, Maweja S, Delvenne P, Rorive A, Collignon J, Garbay J-R, Mathieu M-C, Galatius H, Hoffmann J, Schousen P, Lanng C, Hoerby J, Bruun Rasmussen B, Holtveg H, Moeller-Talman M-L, Abugattas JE, Cotrina JM, Dyer R, Lindtner J, Majdic E, Frkovic-Grazio S, Oehlschlegel C, Ries G, Töpfer M, Lorenz U, Schiltknecht O, Späti B, Ehrsam A, Bamert M, Egli-Tupaj M, Rageth C, Saurenmann E, Tausch C, Caduff R, Moch H, Varga Z, Sarlos D, Kralidis E, Grobholz R, Pagani O, Bronz L, Ghielmini M, Mazzucchelli L, Rusca T, Gyr T, Leidi L, Caccia G, Wyss D, Fey MF, Müller M, Günthert A, Berclaz G, Fleischmann A, Delaloye JF, Treboux A, Lehr H-A, Fiche M, Perey L, Zaman L, Jeanneret Sozzi W, Forbes J, Lindsay DF, Preece DF, Hill J, Jeal P, Smart P, Collins J, Mann GB, Millar R, Murphy C, Buchanan M, Murugasu A, French J, Elder E, Mann L, Moon D, Bilous AM, Pathmanathan N, Howard V, Gill PG, Kollias J, Bochner M, Madigan L, Rippy E, Whitfield R, Farshidi F, Moore K, Sywak M, Tan L, Ross W, Briscoe K, Jones A, Shah A, Lim E, Macindoe R, Spillane A, Moore K, Bonar SF, Carmalt H, West R, Mak C, McKenzie P, Harman R, Gerred S, Juhasz E, Allpress S, Craik J, Campbell I, Chin P, Hayes L, Mayall F, Thorburn M (2018) Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23–01): 10-year follow-up of a randomised, controlled phase 3 trial. Lancet Oncol 19:1385–1393. https://doi.org/10.1016/S1470-2045(18)30380-2CrossRefPubMed Galimberti V, Cole BF, Viale G, Veronesi P, Vicini E, Intra M, Mazzarol G, Massarut S, Zgajnar J, Taffurelli M, Littlejohn D, Knauer M, Tondini C, Di Leo A, Colleoni M, Regan MM, Coates AS, Gelber RD, Goldhirsch A, Boyle F, Jerusalem G, Stahel R, Aebi S, Green M, Karlsson P, Kössler I, Láng I, Hiltbrunner A, Bernhard J, Fournarakou S, Kammler R, Maibach R, Rabaglio M, Ribi K, Roschitzki H, Roux S, Ruepp B, Mahoney C, Price K, Blacher L, Scolese T, Scott K, Lippert S, Zielinski T, Mastropasqua M, Andrighetto S, Dell’Orto P, Renne G, Pruneri G, Dellapasqua S, Iorfida M, Cancello G, Montagna E, Cardillo A, Peruzzotti G, Ghisini R, Luini A, Veronesi U, Intra M, Gentilini O, Zurrida S, Curigliano G, Nole F, Orecchia R, Leonardi MC, Baratella P, Chifu C, Sargenti M, Crivellari D, Morassut S, Mileto M, Piccoli E, Veronesi A, Magri MD, Buonadonna A, Candiani E, Carbone A, Perin T, Volpe R, Roncadin M, Arcicasa M, Coran F, Lagrassa M, Recalcati A, Limonta ME, Tricomi P, Fenaroli P, Candiago E, Cattaneo L, Gianatti A, Santini D, Maweja S, Delvenne P, Rorive A, Collignon J, Garbay J-R, Mathieu M-C, Galatius H, Hoffmann J, Schousen P, Lanng C, Hoerby J, Bruun Rasmussen B, Holtveg H, Moeller-Talman M-L, Abugattas JE, Cotrina JM, Dyer R, Lindtner J, Majdic E, Frkovic-Grazio S, Oehlschlegel C, Ries G, Töpfer M, Lorenz U, Schiltknecht O, Späti B, Ehrsam A, Bamert M, Egli-Tupaj M, Rageth C, Saurenmann E, Tausch C, Caduff R, Moch H, Varga Z, Sarlos D, Kralidis E, Grobholz R, Pagani O, Bronz L, Ghielmini M, Mazzucchelli L, Rusca T, Gyr T, Leidi L, Caccia G, Wyss D, Fey MF, Müller M, Günthert A, Berclaz G, Fleischmann A, Delaloye JF, Treboux A, Lehr H-A, Fiche M, Perey L, Zaman L, Jeanneret Sozzi W, Forbes J, Lindsay DF, Preece DF, Hill J, Jeal P, Smart P, Collins J, Mann GB, Millar R, Murphy C, Buchanan M, Murugasu A, French J, Elder E, Mann L, Moon D, Bilous AM, Pathmanathan N, Howard V, Gill PG, Kollias J, Bochner M, Madigan L, Rippy E, Whitfield R, Farshidi F, Moore K, Sywak M, Tan L, Ross W, Briscoe K, Jones A, Shah A, Lim E, Macindoe R, Spillane A, Moore K, Bonar SF, Carmalt H, West R, Mak C, McKenzie P, Harman R, Gerred S, Juhasz E, Allpress S, Craik J, Campbell I, Chin P, Hayes L, Mayall F, Thorburn M (2018) Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23–01): 10-year follow-up of a randomised, controlled phase 3 trial. Lancet Oncol 19:1385–1393. https://​doi.​org/​10.​1016/​S1470-2045(18)30380-2CrossRefPubMed
Zurück zum Zitat Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, Ollila DW, Hansen NM, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, Hunt KK, Morrow M (2017) Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. J Am Med Assoc 318:918–926. https://doi.org/10.1001/jama.2017.11470CrossRef Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, Ollila DW, Hansen NM, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, Hunt KK, Morrow M (2017) Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. J Am Med Assoc 318:918–926. https://​doi.​org/​10.​1001/​jama.​2017.​11470CrossRef
Zurück zum Zitat Houvenaeghel G, de Nonneville A, Chopin N, Classe J-M, Mazouni C, Chauvet M-P, Reyal F, Tunon de Lara C, Jouve E, Rouzier R, Daraï E, Gimbergues P, Coutant C, Azuar AS, Villet R, Crochet P, Rua S, Bannier M, Cohen M, Boher J-M (2022) The need to tailor the omission of axillary lymph node dissection to patients with good prognosis and sentinel node micro-metastases. Cancer Med. https://doi.org/10.1002/cam4.5257CrossRefPubMedPubMedCentral Houvenaeghel G, de Nonneville A, Chopin N, Classe J-M, Mazouni C, Chauvet M-P, Reyal F, Tunon de Lara C, Jouve E, Rouzier R, Daraï E, Gimbergues P, Coutant C, Azuar AS, Villet R, Crochet P, Rua S, Bannier M, Cohen M, Boher J-M (2022) The need to tailor the omission of axillary lymph node dissection to patients with good prognosis and sentinel node micro-metastases. Cancer Med. https://​doi.​org/​10.​1002/​cam4.​5257CrossRefPubMedPubMedCentral
Zurück zum Zitat Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, Ashikaga T, Weaver DL, Mamounas EP, Jalovec LM, Frazier TG, Noyes RD, Robidoux A, Scarth HMC, Wolmark N (2010) Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 11:927–933. https://doi.org/10.1016/S1470-2045(10)70207-2CrossRefPubMedPubMedCentral Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, Ashikaga T, Weaver DL, Mamounas EP, Jalovec LM, Frazier TG, Noyes RD, Robidoux A, Scarth HMC, Wolmark N (2010) Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 11:927–933. https://​doi.​org/​10.​1016/​S1470-2045(10)70207-2CrossRefPubMedPubMedCentral
Zurück zum Zitat Latosinsky S, Berrang TS, Cutter CS, George R, Olivotto I, Julian TB, Hayashi A, Baliski C, Croshaw RL, Erb KM, Chen J, Baxter NN, Brasel KJ, Brown CJ, Chaudhury P, Cutter CS, Divino CM, Dixon E, Dubois L, Fitzgerald GWN, Henteleff HJA, Kirkpatrick AW, Latosinsky S, MacLean AR, Mastracci TM, McLeod RS, Morris AM, Neumayer LA, Temple LK, McKenzie ME (2012) Axillary dissection versus no axillary dissection in women with invasive breast cancer and sentinel node metastasis. Can J Surg 55:66–69. https://doi.org/10.1503/cjs.036011CrossRefPubMedPubMedCentral Latosinsky S, Berrang TS, Cutter CS, George R, Olivotto I, Julian TB, Hayashi A, Baliski C, Croshaw RL, Erb KM, Chen J, Baxter NN, Brasel KJ, Brown CJ, Chaudhury P, Cutter CS, Divino CM, Dixon E, Dubois L, Fitzgerald GWN, Henteleff HJA, Kirkpatrick AW, Latosinsky S, MacLean AR, Mastracci TM, McLeod RS, Morris AM, Neumayer LA, Temple LK, McKenzie ME (2012) Axillary dissection versus no axillary dissection in women with invasive breast cancer and sentinel node metastasis. Can J Surg 55:66–69. https://​doi.​org/​10.​1503/​cjs.​036011CrossRefPubMedPubMedCentral
Zurück zum Zitat Lyman GH, Giuliano AE, Somerfield MR, Benson AB, Bodurka DC, Burstein HJ, Cochran AJ, Cody HS, Edge SB, Galper S, Hayman JA, Kim TY, Perkins CL, Podoloff DA, Sivasubramaniam VH, Turner RR, Wahl R, Weaver DL, Wolff AC, Winer EP (2005) American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 23:7703–7720. https://doi.org/10.1200/JCO.2005.08.001CrossRefPubMed Lyman GH, Giuliano AE, Somerfield MR, Benson AB, Bodurka DC, Burstein HJ, Cochran AJ, Cody HS, Edge SB, Galper S, Hayman JA, Kim TY, Perkins CL, Podoloff DA, Sivasubramaniam VH, Turner RR, Wahl R, Weaver DL, Wolff AC, Winer EP (2005) American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 23:7703–7720. https://​doi.​org/​10.​1200/​JCO.​2005.​08.​001CrossRefPubMed
Zurück zum Zitat Tsugawa K, Noguchi M, Miwa K, Bando E, Yokoyama K, Nakajima K, Michigishi T, Tonami N, Minato H, Nonomura A (2000) Dye- and gamma probe-guided sentinel lymph node biopsy in breast cancer patients: using patent blue dye and technetium-99m-labeled human serum albumin. Breast Cancer 7:87–94. https://doi.org/10.1007/BF02967195CrossRefPubMed Tsugawa K, Noguchi M, Miwa K, Bando E, Yokoyama K, Nakajima K, Michigishi T, Tonami N, Minato H, Nonomura A (2000) Dye- and gamma probe-guided sentinel lymph node biopsy in breast cancer patients: using patent blue dye and technetium-99m-labeled human serum albumin. Breast Cancer 7:87–94. https://​doi.​org/​10.​1007/​BF02967195CrossRefPubMed
Zurück zum Zitat Tsujimoto M, Nakabayashi K, Yoshidome K, Kaneko T, Iwase T, Akiyama F, Kato Y, Tsuda H, Ueda S, Sato K, Tamaki Y, Noguchi S, Kataoka TR, Nakajima H, Komoike Y, Inaji H, Tsugawa K, Suzuki K, Nakamura S, Daitoh M, Otomo Y, Matsuura N (2007) One-step nucleic acid amplification for intraoperative detection of lymph node metastasis in breast cancer patients. Clin Cancer Res 13:4807–4816. https://doi.org/10.1158/1078-0432.CCR-06-2512CrossRefPubMed Tsujimoto M, Nakabayashi K, Yoshidome K, Kaneko T, Iwase T, Akiyama F, Kato Y, Tsuda H, Ueda S, Sato K, Tamaki Y, Noguchi S, Kataoka TR, Nakajima H, Komoike Y, Inaji H, Tsugawa K, Suzuki K, Nakamura S, Daitoh M, Otomo Y, Matsuura N (2007) One-step nucleic acid amplification for intraoperative detection of lymph node metastasis in breast cancer patients. Clin Cancer Res 13:4807–4816. https://​doi.​org/​10.​1158/​1078-0432.​CCR-06-2512CrossRefPubMed
Zurück zum Zitat Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, Intra M, Veronesi P, Maisonneuve P, Gatti G, Mazzarol G, de Cicco C, Manfredi G, Fernández JR (2006) Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study. Lancet Oncol 7:983–990. https://doi.org/10.1016/S1470-2045(06)70947-0CrossRefPubMed Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, Intra M, Veronesi P, Maisonneuve P, Gatti G, Mazzarol G, de Cicco C, Manfredi G, Fernández JR (2006) Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study. Lancet Oncol 7:983–990. https://​doi.​org/​10.​1016/​S1470-2045(06)70947-0CrossRefPubMed
Zurück zum Zitat Zhang L, Yang Z-Z, Chen X-X, Tuan J, Ma J-L, Mei X, Yu X-L, Zhou Z-R, Shao Z-M, Liu G-Y, Guo X-M (2015) Dose coverage of axillary level I-III areas during whole breast irradiation with simplified intensity modulated radiation therapy in early stage breast cancer patients. Oncotarget 6:18183–18191CrossRefPubMedPubMedCentral Zhang L, Yang Z-Z, Chen X-X, Tuan J, Ma J-L, Mei X, Yu X-L, Zhou Z-R, Shao Z-M, Liu G-Y, Guo X-M (2015) Dose coverage of axillary level I-III areas during whole breast irradiation with simplified intensity modulated radiation therapy in early stage breast cancer patients. Oncotarget 6:18183–18191CrossRefPubMedPubMedCentral
Metadaten
Titel
Omission of axillary lymph node dissection in breast cancer patients with micrometastasis or isolated tumor cells in sentinel lymph nodes: a 12-year experience in a tertiary breast unit
verfasst von
Nuno Sousa
Bárbara Peleteiro
José Luis Fougo
Publikationsdatum
01.01.2025
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 1/2024
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-023-05513-4

Weitere Artikel der Ausgabe 1/2024

Journal of Cancer Research and Clinical Oncology 1/2024 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.